Drug Trial Radar · NCT07536269
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Neurocrine Switzerland GmbHNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Apr 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 months, up to 47 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.
Conditions
- Congenital Adrenal Hyperplasia
Interventions
CrinecerfontDrug
Oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: Day 1 up to 28 weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Neurocrine Clinical Site
San Francisco, California · Recruiting
Neurocrine Clinical Site
Aurora, Colorado · Recruiting
Neurocrine Clinical Site
Hartford, Connecticut · Recruiting
Neurocrine Clinical Site
Atlanta, Georgia · Recruiting
Neurocrine Clinical Site
Chicago, Illinois · Recruiting
Neurocrine Clinical Site
Indianapolis, Indiana · Recruiting
Neurocrine Clinical Site
Ann Arbor, Michigan · Recruiting
Neurocrine Clinical Site
Minneapolis, Minnesota · Recruiting
Neurocrine Clinical Site
Philadelphia, Pennsylvania · Recruiting
Neurocrine Clinical Site
Dallas, Texas · Recruiting
Neurocrine Clinical Site
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.